RSV vaccine Arexvy approved by TGA for Australians 60 and over
Contagious respiratory disease can create more serious symptoms in people with low immunity
www.theguardian.comHere’s the latest I can share based on recent reporting up to 2024-2025.
- Australia approved Arexvy (RSV vaccine by GSK) for adults aged 60 and over, marking the first RSV vaccine authorized in the country. This approval aimed to reduce serious RSV outcomes in older adults and was part of a broader rollout including other RSV products in trials and preparation for wider use.[1][3]
- After the initial approval, RSV vaccines arrived in Australia for the winter season, with Arexvy available by prescription for people 60+, and other RSV measures such as Nirsevimab for infants were implemented through state-funded programs in various regions. Public discussion included calls for potential subsidization or free vaccination for certain groups.[4][5]
- Coverage and access varied by state and there were ongoing updates to immunisation schedules as new vaccines like Abrysvo and Beyfortus entered use in different populations (pregnant women, infants, and older adults). Guidance from Australia’s health authorities emphasised following the Australian Immunisation Handbook and local program availability.[5]
Clarifications and context:
- If you’re looking for the very latest news beyond early 2024, I can search current outlets for any new approvals, price changes, or changes to public funding in 2025–2026, including state-by-state access details in your area of New York City or if you’re asking specifically about Australia. Would you like me to look up the most recent updates now?
Notes on sources:
- Reports on TGA approval for Arexvy in Australia and subsequent public-health discussions are documented in major Australian outlets and university/health-system briefs from early 2024, with ongoing coverage of access and policy discussions.[1][4][5]